Login / Signup

Dual antiplatelet Use for extended period taRgeted to AcuTe Ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: rationale and design.

Joon Tae KimJihoon KangBeom Joon KimJun Yup KimMoon-Ku HanKi-Hyun ChoMan-Seok ParkKang-Ho ChoiJong-Moo ParkKyusik KangYong Soo KimSoo Joo LeeJae Guk KimJae-Kwan ChaDae-Hyun KimTai Hwan ParkSang-Soon ParkJin Kyo ChoiKyung Bok LeeKwang-Yeol ParkHae Bong JeongJun LeeDoo Hyuk KwonYong-Jin ChoKeun-Sik HongHong Kyun ParkByung-Chul LeeKyung-Ho YuMi Sun OhMinwoo LeeDong-Eog KimDong-Seok GwakJay Chol ChoiJoong-Goo KimChul-Hoo KangJee-Hyun KwonWook-Joo KimDong-Ick ShinKyu Sun YumSung-Il SohnHyung Jong ParkJeong-Ho HongChulho KimSang-Hwa LeeJuneyoung LeePhilip B GorelickBo NorrvingHee-Joon Bae
Published in: International journal of stroke : official journal of the International Stroke Society (2023)
URL: https://cris.nih.go.kr/cris. CRIS Registration Number: KCT0004407.
Keyphrases
  • acute ischemic stroke
  • phase iii
  • study protocol
  • cancer therapy
  • phase ii
  • randomized controlled trial
  • open label
  • drug delivery